Multiple System Atrophy (MSA)

Reference work entry

Abstract

Multiple system atrophy (MSA) is a sporadic, rapidly progressive neurodegenerative disorder characterized clinically by a combination of cerebellar dysfunction or parkinsonism and autonomic failure. The histopathological hallmark of MSA is the presence of glial cytoplasmic inclusions composed predominantly of α-synuclein within multiple systems of the brain and the spinal cord accompanied by gliosis and neuronal loss. In the past few years there has been substantial progress in the understanding of the pathogenesis of this fatal neurodegenerative disease. The most recent studies indicate that this is a primary oligodendroglial disorder with synucleinopathy leading to subsequent neurodegeneration.

The authors review the epidemiology, clinical features, diagnostic criteria, neuropathology, pathogenesis, management and therapeutic approaches to this disease.

Keywords

Multiple System Atrophy Progressive Supranuclear Palsy Cerebellar Ataxia Autonomic Failure Multiple System Atrophy Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Adams MR, Van Bogaert L, van der Eecken H (1961) Nigro-striate and cerebello-nigro-striate degeneration (Clinical uniqueness and pathological variability of presenile degeneration of the extrapyramidal rigidity type). Psychiatr Neurol 142:219–259CrossRefGoogle Scholar
  2. Alam M, Smith G, Bleasdale-Barr K et al (1995) Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. J Hypertens 13:1664–1669PubMedGoogle Scholar
  3. Al-Chalabi A, Durr A, Wood NW et al (2009) Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS ONE 4:e7114PubMedCrossRefGoogle Scholar
  4. Angot E, Steiner JA, Hansen C et al (2010) Are synucleinopathies prion-like disorders? Lancet Neurol 9:1128–1138PubMedCrossRefGoogle Scholar
  5. Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55:100–119PubMedCrossRefGoogle Scholar
  6. Armstrong RA, Cairns NJ, Lantos PL (2007) A quantitative study of the pathological changes in white matter in multiple system atrophy. Neuropathology 27:221–227PubMedCrossRefGoogle Scholar
  7. Beck RO, Betts CD, Fowler CJ (1994) Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 151:1336–1341PubMedGoogle Scholar
  8. Ben Shlomo Y, Wenning GK, Tison F et al (1997) Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 48:384–393PubMedCrossRefGoogle Scholar
  9. Bensimon G, Ludolph A, Agid Y et al (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132:156–171PubMedCrossRefGoogle Scholar
  10. Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044–1055PubMedCrossRefGoogle Scholar
  11. Boesch SM, Wenning GK, Ransmayr G et al (2002) Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 72:300–303PubMedCrossRefGoogle Scholar
  12. Bower JH, Maraganore DM, McDonnell SK et al (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49:1284–1288PubMedCrossRefGoogle Scholar
  13. Brooks DJ, Seppi K (2009) Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 24:949–964PubMedCrossRefGoogle Scholar
  14. Casarejos MJ, Menendez J, Solano RM et al (2006) Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97:934–946PubMedCrossRefGoogle Scholar
  15. Chrysostome V, Tison F, Yekhlef F et al (2004) Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 23:201–208PubMedCrossRefGoogle Scholar
  16. Cilia R, Marotta G, Benti R et al (2005) Brain SPECT imaging in multiple system atrophy. J Neural Transm 112:1635–1645PubMedCrossRefGoogle Scholar
  17. Colosimo C, Merello M, Pontieri FE (1996) Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. J Neurol 243:422–425PubMedCrossRefGoogle Scholar
  18. Daniel S (1999) The neuropathology and neurochemistry of multiple system atrophy. In: Mathias CJ, Bannister R (eds) Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. Oxford University Press, OxfordGoogle Scholar
  19. Danzer KM, Haasen D, Karow AR et al (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27:9220–9232PubMedCrossRefGoogle Scholar
  20. Danzer KM, Krebs SK, Wolff M et al (2009) Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem 111:192–203PubMedCrossRefGoogle Scholar
  21. Deguchi K, Ikeda K, Shimamura M et al (2007) Assessment of autonomic dysfunction of multiple system atrophy with laryngeal abductor paralysis as an early manifestation. Clin Neurol Neurosurg 109:892–895PubMedCrossRefGoogle Scholar
  22. Dejerine J, Thomas A (1900) L'atrophie olivo-ponto-cérébelleuse. Nouvelle iconographie de la Salpétrière: Clinique des maladies du système nerveux 13:330–370Google Scholar
  23. Dodel R, Spottke A, Gerhard A et al (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25:97–107PubMedGoogle Scholar
  24. Eckert T, Barnes A, Dhawan V et al (2005) FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26:912–921PubMedCrossRefGoogle Scholar
  25. Eichhorn TE, Oertel WH (2001) Macrogol 3350/electrolyte improves constipation in Parkinson‘s disease and multiple system atrophy. Mov Disord 16:1176–1177PubMedCrossRefGoogle Scholar
  26. Fowler CJ, O’Malley KJ (2003) Investigation and management of neurogenic bladder dysfunction. J Neurol Neurosurg Psychiatry 74(Suppl 4):iv27–iv31PubMedGoogle Scholar
  27. Freeman R (2008) Current pharmacologic treatment for orthostatic hypotension. Clin Auton Res 18(Suppl 1):14–18PubMedCrossRefGoogle Scholar
  28. Frey KA, Koeppe RA, Kilbourn MR et al (1996) Presynaptic monoaminergic vesicles in Parkinson‘s disease and normal aging. Ann Neurol 40:873–884PubMedCrossRefGoogle Scholar
  29. Friess E, Kuempfel T, Modell S et al (2006) Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord 12:432–437PubMedCrossRefGoogle Scholar
  30. Geser F, Wenning GK, Seppi K et al (2006) Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 21:179–186PubMedCrossRefGoogle Scholar
  31. Giannantoni A, Rossi A, Mearini E et al (2009) Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson‘s disease and multiple system atrophy. J Urol 182:1453–1457PubMedCrossRefGoogle Scholar
  32. Gilman S, Markel DS, Koeppe RA et al (1988) Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. Ann Neurol 23:223–230PubMedCrossRefGoogle Scholar
  33. Gilman S, Koeppe RA, Junck L et al (1994) Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 36:166–175PubMedCrossRefGoogle Scholar
  34. Gilman S, Frey KA, Koeppe RA et al (1996) Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Ann Neurol 40:885–892PubMedCrossRefGoogle Scholar
  35. Gilman S, Low P, Quinn N et al (1998) Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 8:359–362PubMedCrossRefGoogle Scholar
  36. Gilman S, Koeppe RA, Junck L et al (1999) Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann Neurol 45:769–777PubMedCrossRefGoogle Scholar
  37. Gilman S, Little R, Johanns J et al (2000) Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology 55:527–532PubMedCrossRefGoogle Scholar
  38. Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676PubMedCrossRefGoogle Scholar
  39. Goetz CG, Tanner CM, Klawans HL (1984) The pharmacology of olivopontocerebellar atrophy. Adv Neurol 41:143–148PubMedGoogle Scholar
  40. Graham JG, Oppenheimer DR (1969) Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32:28–34PubMedCrossRefGoogle Scholar
  41. Halaska M, Ralph G, Wiedemann A et al (2003) Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20:392–399PubMedGoogle Scholar
  42. Hanna PA, Jankovic J, Kirkpatrick JB (1999) Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol 56:90–94PubMedCrossRefGoogle Scholar
  43. Hara K, Momose Y, Tokiguchi S et al (2007) Multiplex families with multiple system atrophy. Arch Neurol 64:545–551PubMedCrossRefGoogle Scholar
  44. Hlavanda E, Kovacs J, Olah J et al (2002) Brain-specific p25 protein binds to tubulin and microtubules and induces aberrant microtubule assemblies at substoichiometric concentrations. Biochemistry 41:8657–8664PubMedCrossRefGoogle Scholar
  45. Holmberg B, Johansson JO, Poewe W et al (2007) Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. Mov Disord 22:1138–1144PubMedCrossRefGoogle Scholar
  46. Horimoto Y, Aiba I, Yasuda T et al (2002) Longitudinal MRI study of multiple system atrophy - when do the findings appear, and what is the course? J Neurol 249:847–854PubMedCrossRefGoogle Scholar
  47. Hsu LJ, Sagara Y, Arroyo A et al (2000) Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157:401–410PubMedCrossRefGoogle Scholar
  48. Hughes AJ, Colosimo C, Kleedorfer B et al (1992) The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 55:1009–1013PubMedCrossRefGoogle Scholar
  49. Hussain IF, Brady CM, Swinn MJ et al (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson‘s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71:371–374PubMedCrossRefGoogle Scholar
  50. Iranzo A, Santamaria J, Tolosa E et al (2004) Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 63:930–932PubMedCrossRefGoogle Scholar
  51. Ito T, Sakakibara R, Yasuda K et al (2006) Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 21:816–823PubMedCrossRefGoogle Scholar
  52. Jain S, Dawson J, Quinn NP et al (2004) Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord 19:1360–1364PubMedCrossRefGoogle Scholar
  53. Jankovic J, Gilden JL, Hiner BC et al (1993) Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95:38–48PubMedCrossRefGoogle Scholar
  54. Jellinger KA (2006) P25alpha immunoreactivity in multiple system atrophy and Parkinson disease. Acta Neuropathol 112:112PubMedCrossRefGoogle Scholar
  55. Jellinger KA, Seppi K, Wenning GK (2005) Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 20(Suppl 12):S29–S36PubMedCrossRefGoogle Scholar
  56. Kahle PJ, Neumann M, Ozmen L et al (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3:583–588PubMedCrossRefGoogle Scholar
  57. Kato S, Nakamura H (1990) Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol 79:584–594PubMedCrossRefGoogle Scholar
  58. Kaufmann H (2008) L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 18(Suppl 1):19–24PubMedCrossRefGoogle Scholar
  59. Kaufmann H, Saadia D, Voustianiouk A et al (2003) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 108:724–728PubMedCrossRefGoogle Scholar
  60. Klos KJ, Bower JH, Josephs KA et al (2005) Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson‘s disease and multiple system atrophy. Parkinsonism Relat Disord 11:381–386PubMedCrossRefGoogle Scholar
  61. Kluin KJ, Gilman S, Markel DS et al (1988) Speech disorders in olivopontocerebellar atrophy correlate with positron emission tomography findings. Ann Neurol 23:547–554PubMedCrossRefGoogle Scholar
  62. Kollensperger M, Stampfer-Kountchev M, Seppi K et al (2007) Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 14:66–72PubMedCrossRefGoogle Scholar
  63. Kollensperger M, Geser F, Ndayisaba JP et al (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25(15):2604–2612PubMedCrossRefGoogle Scholar
  64. Kovacs GG, Gelpi E, Lehotzky A et al (2007) The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathol 113:153–161PubMedCrossRefGoogle Scholar
  65. Lahrmann H, Cortelli P, Hilz M et al (2006) EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 13:930–936PubMedCrossRefGoogle Scholar
  66. Lee PH, Kim JW, Bang OY et al (2008) Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 83:723–730PubMedCrossRefGoogle Scholar
  67. Lees AJ, Bannister R (1981) The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome). J Neurol Neurosurg Psychiatry 44:347–351PubMedCrossRefGoogle Scholar
  68. Lindersson E, Lundvig D, Petersen C et al (2005) p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J Biol Chem 280:5703–5715PubMedCrossRefGoogle Scholar
  69. Liu Z, Sakakibara R, Odaka T et al (2005) Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 20:680–686PubMedCrossRefGoogle Scholar
  70. Low PA, Gilden JL, Freeman R et al (1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. J Am Med Assoc 277:1046–1051CrossRefGoogle Scholar
  71. Luk KC, Song C, O'Brien P et al (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA 106:20051–20056PubMedGoogle Scholar
  72. Mancini F, Zangaglia R, Cristina S et al (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685–688PubMedCrossRefGoogle Scholar
  73. Mathias CJ (2008) L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 18(Suppl 1):25–29PubMedCrossRefGoogle Scholar
  74. Mathias CJ, Fosbraey P, da Costa DF et al (1986) The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Brit Med J 293:353–354, Clin Res.EdCrossRefGoogle Scholar
  75. Mathias CJ, Senard JM, Braune S et al (2001) L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 11:235–242PubMedCrossRefGoogle Scholar
  76. Matsuo A, Akiguchi I, Lee GC et al (1998) Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol 153:735–744PubMedCrossRefGoogle Scholar
  77. Miller DW, Johnson JM, Solano SM et al (2005) Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm 112:1613–1624PubMedCrossRefGoogle Scholar
  78. Muller J, Wenning GK, Wissel J et al (2002) Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 249:300–304PubMedCrossRefGoogle Scholar
  79. Nicoletti G, Lodi R, Condino F et al (2006) Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson‘s disease and progressive supranuclear palsy. Brain 129:2679–2687PubMedCrossRefGoogle Scholar
  80. Nishie M, Mori F, Fujiwara H et al (2004) Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol 107:292–298PubMedCrossRefGoogle Scholar
  81. Orimo S, Kanazawa T, Nakamura A et al (2007) Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113:81–86PubMedCrossRefGoogle Scholar
  82. O'Sullivan JD (2002) Apomorphine as an alternative to sildenafil in Parkinson‘s disease. J Neurol Neurosurg Psychiatry 72:681PubMedCrossRefGoogle Scholar
  83. O'Sullivan JD, Hughes AJ (1998) Apomorphine-induced penile erections in Parkinson‘s disease. Mov Disord 13:536–539PubMedCrossRefGoogle Scholar
  84. Ozawa T (2007) Morphological substrate of autonomic failure and neurohormonal dysfunction in multiple system atrophy: impact on determining phenotype spectrum. Acta Neuropathol 114:201–211PubMedCrossRefGoogle Scholar
  85. Ozawa T, Paviour D, Quinn NP et al (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127:2657–2671PubMedCrossRefGoogle Scholar
  86. Papatsoris AG, Papapetropoulos S, Singer C et al (2008) Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn 27:22–27PubMedCrossRefGoogle Scholar
  87. Papp MI, Lantos PL (1992) Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 107:172–182PubMedCrossRefGoogle Scholar
  88. Papp MI, Lantos PL (1994) The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 117(Pt 2):235–243PubMedCrossRefGoogle Scholar
  89. Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94:79–100PubMedCrossRefGoogle Scholar
  90. Park HJ, Bang G, Lee BR et al. (2010) Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy-parkinsonism. Cell Transplant. http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0169park. Epub ahead of print
  91. Paviour DC, Williams D, Fowler CJ et al (2005) Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. Mov Disord 20:1425–1430PubMedCrossRefGoogle Scholar
  92. Quinn N (1989) Multiple system atrophy – the nature of the beast. J Neurol Neurosurg Psychiatry 52:78–89CrossRefGoogle Scholar
  93. Raffel DM, Koeppe RA, Little R et al (2006) PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 47:1769–1777PubMedGoogle Scholar
  94. Rascol O, Schelosky L (2009) 123I-metaiodobenzylguanidine scintigraphy in Parkinson‘s disease and related disorders. Mov Disord 24(Suppl 2):S732–S741PubMedCrossRefGoogle Scholar
  95. Riley DE (2000) Orthostatic hypotension in multiple system atrophy. Curr Treat Options Neurol 2:225–230PubMedCrossRefGoogle Scholar
  96. Rosenthal G, Gilman S, Koeppe RA et al (1988) Motor dysfunction in olivopontocerebellar atrophy is related to cerebral metabolic rate studied with positron emission tomography. Ann Neurol 24:414–419PubMedCrossRefGoogle Scholar
  97. Saha AR, Ninkina NN, Hanger DP et al (2000) Induction of neuronal death by alpha-synuclein. Eur J Neurosci 12:3073–3077PubMedCrossRefGoogle Scholar
  98. Sakakibara R, Hattori T, Uchiyama T et al (2000) Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 68:65–69PubMedCrossRefGoogle Scholar
  99. Sakakibara R, Yamaguchi T, Uchiyama T et al (2007) Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord 22:1672–1673PubMedCrossRefGoogle Scholar
  100. Schocke MF, Seppi K, Esterhammer R et al (2002) Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 58:575–580PubMedCrossRefGoogle Scholar
  101. Scholz SW, Houlden H, Schulte C et al (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65:610–614PubMedCrossRefGoogle Scholar
  102. Schrag A, Good CD, Miszkiel K et al (2000) Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54:697–702PubMedCrossRefGoogle Scholar
  103. Schrag A, Geser F, Stampfer-Kountchev M et al (2006) Health-related quality of life in multiple system atrophy. Mov Disord 21(6):809–815PubMedCrossRefGoogle Scholar
  104. Seppi K, Poewe W (2010) Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 20:29–55PubMedCrossRefGoogle Scholar
  105. Seppi K, Schocke MF, Esterhammer R et al (2003) Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 60:922–927PubMedCrossRefGoogle Scholar
  106. Seppi K, Peralta C, Diem-Zangerl A et al (2006) Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol 13:1146–1148PubMedCrossRefGoogle Scholar
  107. Shannon JR, Diedrich A, Biaggioni I et al (2002) Water drinking as a treatment for orthostatic syndromes. Am J Med 112:355–360PubMedCrossRefGoogle Scholar
  108. Shults CW, Rockenstein E, Crews L et al (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 25:10689–10699PubMedCrossRefGoogle Scholar
  109. Shy GM, Drager GA (1960) A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol 2:511–527PubMedCrossRefGoogle Scholar
  110. Singer W, Sandroni P, Opfer-Gehrking TL et al (2006) Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 63:513–518PubMedCrossRefGoogle Scholar
  111. Sone M, Yoshida M, Hashizume Y et al (2005) Alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta Neuropathol 110:19–26PubMedCrossRefGoogle Scholar
  112. Song YJ, Lundvig DM, Huang Y et al (2007) p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 171:1291–1303PubMedCrossRefGoogle Scholar
  113. Spillantini MG, Crowther RA, Jakes R et al (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson‘s disease and dementia with Lewy bodies. Neurosci Lett 251:205–208PubMedCrossRefGoogle Scholar
  114. Stefanova N, Tison F, Reindl M et al (2005a) Animal models of multiple system atrophy. Trends Neurosci 28:501–506PubMedCrossRefGoogle Scholar
  115. Stefanova N, Reindl M, Poewe W et al (2005b) In vitro models of multiple system atrophy. Mov Disord 20(Suppl 12):S53–S56PubMedCrossRefGoogle Scholar
  116. Stefanova N, Reindl M, Neumann M et al (2007) Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 22:2196–2203PubMedCrossRefGoogle Scholar
  117. Stefanova N, Poewe W, Wenning GK (2008) Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 210:421–427PubMedCrossRefGoogle Scholar
  118. Stefanova N, Bucke P, Duerr S et al (2009a) Multiple system atrophy: an update. Lancet Neurol 8:1172–1178PubMedCrossRefGoogle Scholar
  119. Stefanova N, Hainzer M, Stemberger S et al (2009b) Striatal transplantation for multiple system atrophy–are grafts affected by alpha-synucleinopathy? Exp Neurol 219:368–371PubMedCrossRefGoogle Scholar
  120. Stemberger S, Poewe W, Wenning GK, Stefanova N (2010) Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp Neurol 224(2):459–464PubMedCrossRefGoogle Scholar
  121. Tada M, Kakita A, Toyoshima Y et al (2009) Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain 132:1810–1819PubMedCrossRefGoogle Scholar
  122. Testa D, Filippini G, Farinotti M et al (1996) Survival in multiple system atrophy: a study of prognostic factors in 59 cases. J Neurol 243:401–404PubMedCrossRefGoogle Scholar
  123. Thobois S, Broussolle E, Toureille L et al (2001) Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. Mov Disord 16:764–765PubMedCrossRefGoogle Scholar
  124. Trojanowski JQ, Revesz T (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33:615–620PubMedCrossRefGoogle Scholar
  125. Ubhi K, Rockenstein E, Mante M et al (2008) Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 19:1271–1276PubMedCrossRefGoogle Scholar
  126. Vodusek DB (2001) Sphincter EMG and differential diagnosis of multiple system atrophy. Mov Disord 16:600–607PubMedCrossRefGoogle Scholar
  127. Walter U, Behnke S, Eyding J (2007) Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 33:15–25PubMedCrossRefGoogle Scholar
  128. Watanabe H, Saito Y, Terao S et al (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125:1070–1083PubMedCrossRefGoogle Scholar
  129. Wenning GK (2005) Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol 28:225–227PubMedCrossRefGoogle Scholar
  130. Wenning GK, Ben Shlomo Y, Magalhaes M et al (1994) Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 117(Pt 4):835–845PubMedCrossRefGoogle Scholar
  131. Wenning GK, Tison F, Elliott L et al (1996) Olivopontocerebellar pathology in multiple system atrophy. Mov Disord 11:157–162PubMedCrossRefGoogle Scholar
  132. Wenning GK, Seppi K, Tison F et al (2002) A novel grading scale for striatonigral degeneration (multiple system atrophy). J Neural Transm 109:307–320PubMedCrossRefGoogle Scholar
  133. Wenning GK, Geser F, Stampfer-Kountchev M et al (2003) Multiple system atrophy: an update. Mov Disord 18(Suppl 6):S34–S42PubMedCrossRefGoogle Scholar
  134. Wenning GK, Colosimo C, Geser F et al (2004) Multiple system atrophy. Lancet Neurol 3:93–103PubMedCrossRefGoogle Scholar
  135. Wenning GK, Stefanova N, Jellinger KA et al (2008) Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 64:239–246PubMedCrossRefGoogle Scholar
  136. Wullner U, Abele M, Schmitz-Huebsch T et al (2004) Probable multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 75:924–925PubMedCrossRefGoogle Scholar
  137. Yamamoto T, Sakakibara R, Uchiyama T et al (2005) When is Onuf's nucleus involved in multiple system atrophy? A sphincter electromyography study. J Neurol Neurosurg Psychiatry 76:1645–1648PubMedCrossRefGoogle Scholar
  138. Yoshida M (2007) Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 27:484–493PubMedCrossRefGoogle Scholar
  139. Young TM, Mathias CJ (2004) The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry 75:1737–1741PubMedCrossRefGoogle Scholar
  140. Zhu S, Stavrovskaya IG, Drozda M et al (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74–78PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Gregor K. Wenning
    • 1
  • Florian Krismer
    • 1
  • Sid Gilman
    • 2
  1. 1.Division of Clinical Neurobiology, Department of NeurologyMedical UniversityInnsbruckAustria
  2. 2.Department of NeurologyUniversity of MichiganAnn ArborUSA

Personalised recommendations